KIT-13

KIT-13 is a **novel plasmalogen derivative** reported in a 2024 peer-reviewed publication as a preclinical neuroactive lipid therapeutic candidate. Chemically, it is **1-O-octadecyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolamine**, a synthetic ether phospholipid designed to mimic and outperform natural plasmalogens. In mouse and cell-based studies, KIT-13 enhanced memory and cognition, increased brain-derived neurotrophic factor signaling, promoted neurogenesis, reduced neuronal apoptosis, and attenuated neuroinflammation including reduced pro-inflammatory cytokine expression and glial activation. The available public evidence supports KIT-13 as an **early preclinical small-molecule lipid candidate** being explored for neurodegenerative and cognition-related indications, especially **Alzheimer's disease** and related neuroinflammatory disorders, but no clinical-stage development, brand name, or commercial manufacturer was identified from the provided source.

Other names

1-O-octadecyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolamine